Physician profile
Derek Cheng
NPI 1013356716
$4,379.27
in general payments reported to CMS, 2019-2025
16 companies · $1,037 in 2025
The $1,037 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $240 · 2021: $483 · 2022: $404 · 2023: $524 · 2024: $902 · 2025: $1,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,464.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $1,928.49 | 2020-2025 | Xcopri |
| Abbvie INC. | $828.54 | 2021-2025 | |
| Ucb, INC. | $208.92 | 2019 | |
| Biogen, INC. | $171.26 | 2021-2023 | Vumerity |
| Abbott Laboratories | $142.25 | 2019 | |
| Genentech USA, INC. | $139.14 | 2019 | |
| Argenx US, INC. | $125.00 | 2025 | Vyvgart |
| Genzyme Corporation | $125.00 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $118.05 | 2021 | |
| Medtronic USA, INC. | $113.47 | 2020 | |
| Alexion Pharmaceuticals, INC. | $102.50 | 2019 | |
| Amgen INC. | $99.18 | 2022 | |
| Acclarent, INC | $80.35 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $71.40 | 2022 | |
| Adamas Pharmaceuticals, INC. | $70.40 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuropace, INC. | $55.32 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Cheng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.